INDIANAPOLIS, Jan. 21, 2016 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) has approved Eli Lilly and Company's (NYSE: LLY) Humulin ® R U-500 KwikPen ® (insulin human injection) 500 units ...
BD announced the launch of the BD U-500 Insulin Syringe, the first insulin syringe designed for patients with diabetes taking Humulin R U-500 insulin (regular insulin [human, rDNA origin]; Eli Lilly).
Eli Lilly announced the launch of Humulin R U-500 KwikPen (insulin human injection), a prefilled device containing a highly concentrated formulation of insulin. Eli Lilly announced the launch of ...
The BD U-500 Insulin Syringe is specifically designed to administer the Humulin R U-500 insulin among patients properly. The Humulin R U-500 insulin is prescribed to patients who need a higher dose of ...
The U.S. Food and Drug Administration (FDA) has approved Eli Lilly and Company's (NYSE: LLY) Humulin ® R U-500 KwikPen ® (insulin human injection) 500 units/mL, a pre-filled device containing Humulin ...
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company announced today the launch of the BDâ„¢ U-500 Insulin Syringe, the first insulin syringe developed for people ...
The US Food and Drug Administration (FDA) has approved the first prefilled pen device containing concentrated U-500 strength insulin (Humulin R U-500 KwikPen [insulin human injection] 500 units/mL, ...
The US Food and Drug Administration approved a dedicated syringe for the administration of Humulin R U-500 insulin, which is now the only device approved for use with U-500 insulin vial. Humulin R ...
Please provide your email address to receive an email when new articles are posted on . The FDA approved a dedicated syringe for the administration of Humulin R U-500 insulin, eliminating the need for ...
Insulet To Develop New Version Of The OmniPod Insulin Pump For Use With Humulin R U-500 Concentrated Insulin For People With Type 2 Diabetes Bedford, MA (Marketwired) - Insulet Corporation (NASDAQ: ...
DANBURY, CT-- Biodel Inc. (BIOD) announced positive preliminary results from Study 3-152, a Phase 2a clinical trial comparing Biodel's proprietary, concentrated insulin formulation BIOD-531 to ...